The PRISM Parkinson’s Research Study is evaluating an investigational drug to determine if it might slow down the progression of Parkinson’s disease (PD). About 240 men and women across approximately 60 clinical sites in North America will enroll in this study. Patients who enroll in this study will receive the study drug weekly over a period of 36 weeks. Study participants will have about 10 scheduled in-person visits to the study center, and 5 scheduled telephone visits. Two of these visits will be follow-up visits once the 36-week study treatment period ends. Those who enroll can expect to be in the study for a total of 44 weeks.
Other criteria for eligibility apply. Study participants receive study-related medical exams and study drug at no cost. Compensation for time and travel may be available.